Why Biotech Investors Need A Research Ombudsman
Digital health and biotech investors are being left in the dark about the quality of research emerging from local health sciences companies and academic institutes, according to Executive Chairman, Nick Northcott. Read the full article by Yolanda Redrup published in The Australian Financial Review and insights from Nick to find out more about why biotech investors need a research ombudsman.
Read more: